These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 25410881)

  • 1. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
    BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
    Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
    Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
    Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
    Kwok CW; Treeck O; Buchholz S; Seitz S; Ortmann O; Engel JB
    Target Oncol; 2015 Sep; 10(3):365-73. PubMed ID: 25293576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
    Gründker C; Wokoun U; Hellriegel M; Emons G
    J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
    Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F
    Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
    Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
    Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.
    Popovics P; Schally AV; Szalontay L; Block NL; Rick FG
    Oncotarget; 2014 Jun; 5(12):4567-78. PubMed ID: 24994120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
    Buchholz S; Seitz S; Schally AV; Engel JB; Rick FG; Szalontay L; Hohla F; Krishan A; Papadia A; Gaiser T; Brockhoff G; Ortmann O; Diedrich K; Köster F
    Int J Oncol; 2009 Oct; 35(4):789-96. PubMed ID: 19724914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G; Sindermann H; Engel J; Schally AV; Gründker C
    Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH).
    Buchholz S; Seitz S; Engel JB; Montero A; Ortmann O; Perez R; Block NL; Schally AV
    Horm Mol Biol Clin Investig; 2012 Apr; 9(1):87-94. PubMed ID: 25961354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
    Jaszberenyi M; Schally AV; Block NL; Nadji M; Vidaurre I; Szalontay L; Rick FG
    Oncotarget; 2013 Mar; 4(3):422-32. PubMed ID: 23518876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.